theMednetRegister

Rheumatology

Diffuse Parenchymal Lung Disease   

Questions discussed in this category

How do you approach PJP prophylaxis in patients with rheumatic disease on corticosteroids?
Does the presence of ILD change your approach?
3 Answers available
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
4 Answers available
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Do you use TNF-i or MMF?
1 Answer available
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
Is this managed as CTD-ILD with immunosuppressive +/- anti-fibrotic agents?
1 Answer available
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
1 Answer available
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
1 Answer available
How do you approach management of new onset ILD in a patient with RA who is otherwise well controlled on methotrexate or leflunomide?
1 Answer available
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
CT changes are subsolid and ground glass nodules.
1 Answer available
How do you approach the treatment of indeterminate UIP on HRCT with grossly positive MPO antibody and no other features consistent with AAV?
1 Answer available
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
Do you ever start mycophenolate without steroids?
1 Answer available
How do you manage diarrhea in a patient with CTD-ILD on MMF who was recently started on full dose nintedanib?
5 Answers available
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
1 Answer available
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
1 Answer available
What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?
2 Answers available
What is your approach in differentiating IPAF (interstitial pneumonia with autoimmune features) versus "CTD ILD" in patients with serologic abnormalities but do not fulfill criteria for autoimmune disease?
1 Answer available
What is your preferred steroid sparing agent in the treatment of Sjögren associated LIP?
2 Answers available
When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?
Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?
6 Answers available
Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?
3 Answers available
What dose and duration of steroid therapy do you use in steroid responsive ILD?
1 Answer available
Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD who have not yet demonstrated evidence of a progressive phenotype?
1 Answer available


Papers discussed in this category

Annals of the rheumatic diseases, 2022 Nov 03
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.
Frontiers in immunology, 2021 Apr 12
Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumonia in Immunocompromised Patients.
The European respiratory journal, 2015-10
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Arthritis & rheumatology (Hoboken, N.J.), 2017-03
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Lancet Respir Med, 2021 Jan
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2022 Jun 11
Identification and Prognosis of Patients With Interstitial Pneumonia With Autoimmune Features.
European respiratory review : an official journal of the European Respiratory Society, 2021 Dec 22
Interstitial pneumonia with autoimmune features: challenges and controversies.
The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Respirology, 2013 Nov 29
Rituximab in severe, treatment-refractory interstitial lung disease.
Respir Res, 2022 Jun 21
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
European journal of internal medicine, 2023 Sep 04
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
Autoimmunity reviews, 2021 Apr 19
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Clin Med Insights Circ Respir Pulm Med, 2021 Mar 30
Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib.
Cureus, 2022 Sep 06
Mycophenolate Mofetil-Induced Cytomegalovirus Colitis in a Patient With Polymyositis.
Respiratory medicine, 2016-12
Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.
Chest, 2021 Feb
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
European respiratory review : an official journal of the European Respiratory Society, 2021 Nov 08
Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review.
Rheumatology (Oxford, England), 2021 Dec 24
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
Journal of the Endocrine Society, 2022 Dec 02
Perioperative Evaluation and Management of Patients on Glucocorticoids.
Diagnostics (Basel, Switzerland), 2021 Apr 20
Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.
Rheumatology (Oxford),
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
Rheumatology (Oxford, England), 2023 Dec 01
Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2004-03
Leflunomide for chronic sarcoidosis.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2000-03
Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.
Chest, 2003-07
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.
American journal of respiratory and critical care medicine, 2006-10-01
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
Diagnostics (Basel, Switzerland), 2024 Jan 23
A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis.
Chest, 1999 Aug
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group.
Respiration; international review of thoracic diseases, 2012 Dec 29
Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.